Scarica l'app Stockscreener
4.66
2.10%
-0.10
Dopo l'orario di chiusura:
4.69
0.03
+0.64%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Oramed Pharmaceuticals Inc Borsa (ORMP) Ultime notizie
Oramed shifts focus to investments, sees gains but faces cash and dilution risks - Pluang
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP) - Seeking Alpha
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) Share Price, ORMP Stock News, ORMP Share Price & Updates - Kalkine
Oramed backs exoskeleton maker Lifeward (NASDAQ: LFWD) in milestone-based funding deal - Stock Titan
Oramed Pharmaceuticals (ORMP) Rises 3.2% to $5.0, Testing Key $5.25 ResistanceTPO Profile - vinanet.vn
Oramed Pharmaceuticals stock holds at $5 after recent biotech volatility - ad-hoc-news.de
Biotech Stocks At 52-Week HighsNEO, BLSM, RVMD, ORMP, CADL - RTTNews
Oramed Pharmaceuticals Incorporated Actuals & Estimates (TRADEGATE:OJU1) - TradingView
Top Penny Stocks To Watch In August 2026 - simplywall.st
Oramed (ORMP) EPS and Revenue: Profit Per Share Surpasses Its Benchmark in the Latest Reading; Post-Earnings: The Stock Ends Up 4.60% on the DayDividend Earnings Report - vinanet.vn
Nano Dimension Names Nadav Kidron to Board, Exclusivity with Infinite Epigenetics Ends - Kalkine Media
Nano Dimension Appoints Nadav Kidron to Lead Capital Allocation Review - citybiz
Oramed CEO Joins Nano Dimension Board as Directors Weigh Capital Options - Stock Titan
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee - Yahoo Finance
MSN Money - MSN
ORMP Price Today: Oramed Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC - MEXC
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to Buy Rating - MarketBeat
Aquamarine Financial (ORMP) discloses 6.04% Oramed ownership in 13G/A - Stock Titan
ORMP Q4 2025 Earnings: EPS Beat Drives Stock Gain as Revenue Remains N/AReturn On Assets - vinanet.vn
Oramed Pharmaceuticals (NASDAQ:ORMP) Releases Quarterly Earnings Results - marketbeat.com
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a shareEarnings Preview - TradingView
Oramed: Q2 Earnings Snapshot - marketscreener.com
ORAMED PHARMACEUTICALS INC. 2Q 2026: Revenue $0 Net income $78.16M, EPS $1.84— 10-Q Summary - TradingView
Oramed Pharmaceuticals (NASDAQ: ORMP) pivots to investment model with $116M profit - Stock Titan
Oramed Pharmaceuticals Inc (ORMP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oramed Pharmaceuticals (ORMP) Projected to Release Quarterly Earnings on Thursday - marketbeat.com
Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Above 200 Day Moving AverageWhat's Next? - MarketBeat
Oramed Pharmaceuticals (ORMP) Holds Steady at $4.33 as Range-Bound Trading PersistsSpring Pattern - dars.gov.et
ORMP | Oramed Pharmaceuticals Inc. Executive Compensation - Quiver Quantitative
ORMP Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Oramed Pharmaceuticals announces annual shareholder meeting - Bitget
ORAMED PHARMACEUTICALS INC. SEC Filing (Aug 3, 2026) | ORMP ARS - Stock Titan
Oral Biologics Drugs Companies at 22.65% CAGR By 2034 - Fortune Business Insights
Oramed Pharmaceuticals Market Sentiment - Benzinga
Oramed Pharmaceuticals Inc (ORMP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Cash Flow - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Balance Sheet - TradingKey
ORMP Q4 2025 Earnings: EPS Surges Past Estimates Despite Revenue Absence, Stock Declines 3.13%Earnings Forecast Report - dars.gov.et
ORMP|Oramed Pharmaceuticals Inc|Price:4.762|Chg%:+0.192 - TradingKey
Oramed Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:ORMP - TradingView
TradingKey - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oramed Pharmaceuticals Inc (OJU1.SG) stock price, news, quote and history - Yahoo Finance UK
Nano Dimension Ltd. (NASDAQ: NNDM) sees Oramed stake drop to 3.3% - Stock Titan
AlTi Global Leads Our Selection Of 3 Promising Penny Stocks - simplywall.st
Oramed stock trades quietly as diabetes pill strategy pivots after FDA setback - Ad-hoc-news.de
Oramed Pharmaceuticals Q4 2025 Earnings: EPS Surprise Driven by Non-Operating Gains; Stock Slips Despite BeatLong-Term Guidance - vinanet.vn
Oramed Pharmaceuticals Inc. Net Worth (2026) - GuruFocus
Price to sales forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
Enterprise value to EBIT forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
Oramed Pharmaceuticals highlights oral drug platform as investors assess long-term prospects - Ad-hoc-news.de
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet - AOL.com
Oramed Pharmaceuticals outlines its oral drug strategy as Nasdaq-listed biotech pursues long-term gr - Ad Hoc News
ORMP Q4 2025 Earnings: Positive EPS Surprise Despite Revenue Absence, Stock Falls 5.91%Analyst Drop Coverage - dars.gov.et
Price to earnings forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
Price to book forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
Oramed Pharmaceuticals stock holds its ground. Investors await the next company update. - ad-hoc-news.de
ORMP News | ORAMED PHARMACEUTICALS INC (NASDAQ:ORMP) - ChartMill
Insider Sell: Avraham Gabay Sells 73,360 Shares of Oramed Pharma - GuruFocus
Oramed Pharmaceuticals COO & Cbo Sold Shares Worth Over $611K - TradingView
Oramed (NASDAQ: ORMP) COO sells 137K shares after option exercise - Stock Titan
ORAMED (NASDAQ: ORMP) CFO executes pre-planned sale of 73,360 shares - Stock Titan
Oramed Pharmaceuticals Incorporated Financial Disclosures & SEC Filings - TradingView
0.24%
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):